Therefore, and given the multitude of indications for the relevant oncogenic role of RSPOs, it remains valuable to further investigate the clinical potential of anti-RSPO monoclonal antibodies specifically in cancer patients that harbor RSPO alterations. The gene discussed is RSPO1; the disease is cancer.